UAE Minimally Invasive Biopsy Techniques Market Assessment, By Product Offered, By Technique, By Circulating Biomarker, By Application, By End-user, By Region, Opportunities and Forecast, 2016-2030F

UAE minimally invasive biopsy techniques market size was valued at USD 101.4 million in 2022, which is expected to reach USD 179.5 million in 2030, with a CAGR of 7.4% for the forecast period between 2023 and 2030F. Minimally invasive biopsy techniques are becoming increasingly popular due to their accuracy and safety as well as their ability to provide quicker results, compared to traditional biopsy methods. The UAE government has taken steps to develop its healthcare infrastructure, which has resulted in a higher demand for minimally invasive biopsy techniques. The government has encouraged the growth of the private healthcare sector, which has further driven the demand for these techniques. Another factor contributing to the growth of UAE minimally invasive biopsy techniques market is, the rising incidence of cancer in the region. The use of minimally invasive biopsy techniques for the diagnosis of cancer is gaining popularity due to its higher accuracy and lower risk of complications compared to traditional biopsy methods.

Furthermore, technological advancements in minimally invasive biopsy techniques have made them more effective and safer for patients. These advancements have made the procedures less invasive, resulting in quicker recovery times and fewer complications. In addition, UAE has a high standard of living, and its citizens are willing to pay for high-quality healthcare services, including minimally invasive biopsy techniques. It has led to the development of advanced healthcare facilities that offer the latest in minimally invasive biopsy techniques. For instance, The ClearLLab 10C System from Beckman Coulter, paired with its specialized kits, is an innovative flow cytometry solution for comprehensive immunophenotyping of hematopoietic malignancies. This advanced platform enables simultaneous analysis of ten colors, enhancing the precision and speed of disease identification in clinical laboratories. Its robust capabilities significantly contribute to accurate diagnoses and informed treatment decisions for patients with complex hematological conditions.

Growing Healthcare Infrastructure and Increasing Investments in Healthcare

UAE has been investing heavily in its healthcare infrastructure, with a focus on providing high-quality medical care to its citizens and residents. As a result, the demand for minimally invasive biopsy techniques has been increasing in recent years. Minimally invasive biopsies offer numerous benefits over traditional biopsies, including less pain, shorter recovery times, and fewer complications. In addition, the growing prevalence of cancer in UAE has further driven the demand for minimally invasive biopsy techniques, as early detection is crucial for successful treatment. As a result, the market for minimally invasive biopsy techniques in UAE is expected to grow significantly in the coming years, with increasing investments in healthcare infrastructure and advancements in medical technology. For example, in October 2022, a team of physicians at Sheikh Khalifa Medical City (SKMC), a prominent facility under the Abu Dhabi Health Services Company (SEHA), achieved a significant milestone by performing laser ablation on benign thyroid nodules in a 48-year-old woman, Rula Shukair. This minimally invasive technique proved highly effective, allowing the patient to circumvent traditional surgical removal of the thyroid gland, and freeing her from the need for lifelong medication to regulate normal metabolism.

Demand for Early Detection

The demand for early detection is a powerful driving force in the UAE minimally invasive biopsy techniques market. With a heightened focus on proactive healthcare, there's a growing urgency to detect diseases at their earliest stages. Minimally invasive biopsy techniques play a pivotal role in fulfilling the demand, offering the ability to identify conditions such as cancer, cardiovascular diseases, and other critical illnesses in their nascent phases. These techniques, such as liquid biopsies and advanced imaging-guided procedures, provide a less invasive and more accessible means for early disease detection, thereby enabling prompt intervention, personalized treatment strategies, and improved patient outcomes. As a result, the UAE healthcare landscape increasingly values minimally invasive biopsies as a vital tool in the quest for proactive healthcare and disease prevention.

Emergence of New Technologies and Techniques

In recent years, UAE has seen the emergence of modern technologies and techniques for minimally invasive biopsy procedures. One of the most promising advancements is the use of ultrasound-guided biopsies, which allow for greater precision and accuracy when targeting specific areas of the body. Additionally, advancements in imaging technologies, such as computed tomography (CT) and magnetic resonance imaging (MRI), have improved the visualization of tissues, making it easier to identify and biopsy suspicious areas. Other emerging techniques include liquid biopsy, which involves the analysis of bodily fluids such as blood or urine to detect cancer, and robotic-assisted biopsies, which allow for greater control and precision during the procedure. These innovative technologies and techniques are expected to further drive the growth in UAE minimally invasive biopsy market, as they offer patients safer, more accurate and less invasive diagnostic options. For example, in the year 2022, Thermo Fisher Scientific made a groundbreaking debut with the introduction of The Absolute Q Liquid Biopsy dPCR Assays. The Absolute Q™ Liquid Biopsy dPCR Assays are a revolutionary diagnostic tool that uses digital polymerase chain reaction (dPCR) technology to detect and quantify genetic material in liquid samples. Specifically designed for liquid biopsies, these assays provide unparalleled sensitivity and accuracy for the detection of circulating tumor DNA (ctDNA) and other biomarkers. The advancement offer crucial insights for cancer monitoring and personalized treatment strategies.

Impact of COVID-19

The outbreak of the pandemic has led to a decrease in demand for elective procedures, including minimally invasive biopsies, as many patients have postponed non-urgent medical procedures due to safety concerns and financial constraints. Additionally, the pandemic has disrupted global supply chains, leading to shortages of medical devices, including minimally invasive biopsy devices. However, the UAE government's response to the pandemic has been swift and effective, with measures put in place to ensure the continued provision of essential medical services, including diagnostic procedures like minimally invasive biopsies. As the vaccination campaign rolls out, it is expected that demand for minimally invasive biopsies will rebound as patients feel more comfortable seeking medical care and hospitals return to more normal operations.

Key Player Landscape and Outlook

In UAE minimally invasive biopsy techniques market, several key players are contributing to the advancement of healthcare and diagnosis. Companies like Medtronic plc, Olympus Corporation, Stryker Corporation, BD (Becton Dickinson and Company), and Cook Medical are among the prominent players in this sector. These companies are actively engaged in developing innovative biopsy devices and technologies to enhance accuracy, minimize patient discomfort, and improve overall diagnostic outcomes. The UAE's growing healthcare infrastructure, rising awareness about the benefits of early diagnosis, and increasing prevalence of cancer are driving the demand for minimally invasive biopsy procedures. As a result, the market outlook for minimally invasive biopsy techniques in the UAE is positive, and the competition among key players is likely to remain robust as they strive to cater to the rising demand and provide innovative solutions to meet the country's healthcare needs. For instance, PerkinElmer unveiled the PG-Seq™ Rapid v2 kit in 2022, specifically designed to assess DNA at picogram levels sourced from embryo biopsies, catering to pre-implantation genetic testing needs involving single or multi-cells, as well as scenarios with low template DNA.